This study aimed to investigate the pivotal and well-established molecular breast cancer markers, ER, PR, and HER2, in the respective subtypes of human high-grade DCIS, aiming to identify those DCIS lesions that most probably will progress to IBC. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.